IDXG Interpace Biosciences Inc

Price (delayed)

$10.35

Market cap

$42.57M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$5.97

Enterprise value

$47.55M

Highlights
Interpace Biosciences's gross profit has surged by 56% YoY and by 15% QoQ
IDXG's EPS is up by 31% year-on-year and by 18% since the previous quarter
The company's debt has surged by 138% QoQ
Interpace Biosciences's quick ratio has shrunk by 63% YoY and by 13% QoQ

Key stats

What are the main financial stats of IDXG
Market
Shares outstanding
4.11M
Market cap
$42.57M
Enterprise value
$47.55M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.43
Earnings
Revenue
$33.17M
EBIT
-$23.54M
EBITDA
-$17.82M
Free cash flow
-$13.4M
Per share
EPS
-$5.97
Free cash flow per share
-$3.28
Book value per share
-$8.11
Revenue per share
$8.11
TBVPS
$6.16
Balance sheet
Total assets
$43.86M
Total liabilities
$30.22M
Debt
$8.42M
Equity
-$32.9M
Working capital
-$6.2M
Liquidity
Debt to equity
-0.26
Current ratio
0.7
Quick ratio
0.55
Net debt/EBITDA
-0.28
Margins
EBITDA margin
-53.7%
Gross margin
37.1%
Net margin
-72.8%
Operating margin
-72.4%
Efficiency
Return on assets
-48.1%
Return on equity
N/A
Return on invested capital
-210%
Return on capital employed
-100.6%
Return on sales
-71%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IDXG stock price

How has the Interpace Biosciences stock price performed over time
Intraday
3.5%
1 week
0.98%
1 month
29.38%
1 year
93.46%
YTD
229.62%
QTD
118.12%

Financial performance

How have Interpace Biosciences's revenue and profit performed over time
Revenue
$33.17M
Gross profit
$12.3M
Operating income
-$24.02M
Net income
-$24.16M
Gross margin
37.1%
Net margin
-72.8%
Interpace Biosciences's gross profit has surged by 56% YoY and by 15% QoQ
The company's net margin rose by 34% YoY and by 11% QoQ
The company's operating margin rose by 33% YoY and by 12% QoQ
Interpace Biosciences's gross margin has increased by 28% YoY and by 12% QoQ

Growth

What is Interpace Biosciences's growth rate over time

Valuation

What is Interpace Biosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
1.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.43
IDXG's EPS is up by 31% year-on-year and by 18% since the previous quarter
Interpace Biosciences's equity has decreased by 13% from the previous quarter
The price to sales (P/S) is 156% higher than the last 4 quarters average of 0.5 and 28% higher than the 5-year quarterly average of 1.0
The revenue has grown by 22% YoY and by 2.4% from the previous quarter

Efficiency

How efficient is Interpace Biosciences business performance
IDXG's return on sales is up by 34% year-on-year and by 11% since the previous quarter
Interpace Biosciences's ROA has increased by 14% YoY and by 11% from the previous quarter
The ROIC is up by 8% year-on-year and by 6% since the previous quarter

Dividends

What is IDXG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IDXG.

Financial health

How did Interpace Biosciences financials performed over time
The company's total assets is 45% higher than its total liabilities
Interpace Biosciences's quick ratio has shrunk by 63% YoY and by 13% QoQ
Interpace Biosciences's current ratio has shrunk by 61% YoY and by 9% QoQ
The company's debt is 126% higher than its equity
The company's debt has surged by 138% QoQ
Interpace Biosciences's debt to equity has shrunk by 117% QoQ and by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.